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InTroducTIon
Sarcomatoid renal-cell carcinoma is a rare and important cancer accounting for up to 5% of all renal-cell carcinoma subtypes.
It is characterised with a very aggressive course of disease, rapid spread of cancer cells (mostly into lungs, bones, liver and lymph glands), short survival period (median survival rate 4-9 months), early recurrence of the disease after nephrectomy and high resistance to various forms of systemic treatment [1] .
cASe reporT
The study describes a case of 58 year old woman after left ne- shown that better responses were observed in patients with the percentage of sarcomatoid pattern higher than 50% [8] .
Summary of results in Table 2 .
The alternative method of systemic treatment in this group of patients is the introduction of VGRF inhibitors with particular focus on sorafenib [4] [5] [6] . In a group of 43 patients, in 19% PR (9) in 49% SD (21), and in 33% (14) PD was achieved. Median PFS and OS was 5.3 and 11.8 months respectively [6] . The results were achieved in the group of patients where the sarcomatoid pattern was lower than 20% of the primary tumour.
Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report A. Gębara-Puchniarz, B. Hryciuk, R. Stec, C. Szczylik, B. Grala, W. Kozłowski Three of these four patients had pathology reviewed centrally. 1 For at least 56 days. includes 1 unconfirmed Pr. 2 includes 4 patients with stable disease for 51-55 days.
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• elevated serum lactate dehydrogenase
• elevated serum calcium
• anemia
• absence of prior nephrectomy.
In group of 39 patients had sarcomatoid RCC ORR was 26%, and in group of 33 with poor-risk RCC ORR was 24%. • neutropenia (n = 20)
• anemia (n = 10)
• fatigue (n = 7).
concLuSIon
The doxorubicin-and gemcitabine-based chemotherapy seems to be a favourable therapeutic option for patients in sarcomatoid component of the renal-cell cancer in which the nephrectomy was followed by the progression of the disease.
Based on literature data and own experience it seems that at present the optimum method of management of patients with renal cell carcinoma with sarcomatoid component is in the first line: surgery (including treatment of metastatic lesions) [1, 7] and in case of a failure, introduction of systemic treatmentdoxorubicin and gemcitabine-based chemotherapy [2, 3] . It is important to examine morphological feature of metastases which develop during the disease. Their character could be different than in the primary tumor. This may determine further action.
The development of optimum method of systemic treatment requires further prospective randomised trials.
